SFB1112: The incorporation of EPR probes and drugs into nanocarriers is a promising diagnostic and therapeutic approach. The objective of this project is to investigate the penetration of various nanosystems into dermal cells and into the skin as well as the delivery and release of drug analogues and labeled drugs in the skin. For this purpose, the drugs tacrolimus, S1P (sphingosine-1-phosphate) and dexamethasone are labeled with EPR probes and subsequently loaded to the nanosystems. The nanosystems provided by the project partners permit a selective pH- or temperature-triggered release of the drugs. Triggered release via light-sensitive systems is possible, too. Slow hydrolysis of the nanosystems in the skin provides another option of triggering. The synthesized systems are initially investigated in vitro for drug location and release using multi-frequency EPR and the microenvironment of the incorporated labeled drug or drug analogue is determined. In addition to the in vitro investigations of the drug–carrier complex in solutions, the microenvironment of the labeled drugs shall also be observed in cells and in the skin. Furthermore, the drug release will be investigated at a cellular level using human cell lines of the skin and – after penetration of the systems – in excised human, porcine or murine skin.
Laufzeit: 10/2013 - 06/2018
Mittelgeber: Freie Universität Berlin
Kontakt
Chemikerin und Medizinphysikerin, Leiterin des CCPCharité – Universitätsmedizin Berlin
Postadresse:Charitéplatz 110117 Berlin
Campus- bzw. interne Geländeadresse:Luisenstraße 2
Zurück zur Übersicht